Equity Details
Price & Market Data
Price: $26.90
Daily Change: +$0.60 / 2.23%
Daily Range: $25.63 - $27.03
Market Cap: $2,643,450,880
Daily Volume: 1,265,738
Performance Metrics
1 Week: 7.32%
1 Month: 13.58%
3 Months: 10.91%
6 Months: -12.37%
1 Year: -25.63%
YTD: 16.70%
About Ultragenyx Pharmaceutical Inc. (RARE)
Get insights into Ultragenyx Pharmaceutical Inc. (RARE)'s financial health. With a price of 26.90, the stock shows a +$0.60 / 2.23% daily change. Its market cap is 2,643,450,880. Detailed performance for 1-month (13.58%) and 52-week (-25.63%) periods are crucial.
Company Details
Employees: 1371
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.